Tenpoint Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tenpoint Therapeutics Ltd. - overview
Established
2020
Location
London, -, UK
Primary Industry
Biotechnology
About
Based in Cambridge, UK, and founded in 2020 by Pete Coffey, Lyndon da Cruz, Deniz Dalkara, Olivier Goureau, Vanessa King, Thomas Reh, and José-Alain Sahel, Tenpoint Therapeutics Limited, a. k. a. Tenpoint Therapeutics operates as a biotech company that is developing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases.
In January 2026, Tenpoint Therapeutics Limited raised USD 85 million in series B funding led by Janus Henderson Investors, with participation from EQT, Hillhouse Investment, British Business Bank, EQT Life Sciences, Sofinnova Partners, and F-Prime Capital. The round was part of a larger USD 235 million series B and venture debt funding. As of July 2023, Eddy Anglade is the CEO of the company. The company is developing engineered cell-based therapeutics and in vivo reprogramming to reverse vision loss caused by the deterioration of functional tissue.
Tenpoint Therapeutics also develops a regenerative medicine platform that helps replace cells destroyed by both age-related and inherited ocular diseases. Tenpoint Therapeutics plans to use its proceeds from July 2023 funding to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.
Current Investors
Sofinnova Partners, Qiming Venture Partners, Eight Roads Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Optometrists & Opticians Products and Services
Website
www.tenpointtherapeutics.com
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Tenpoint Therapeutics Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Visus Therapeutics Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.